Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 426 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Vascular Disease Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

NCT06257082
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Online Survey
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

NCT04611880
View directory record Official record
Conditions
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Interventions
Crizanlizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

NCT00387582
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab (Lucentis), Argon Laser
Drug · Procedure
Lead sponsor
Rocky Mountain Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Computer-based Screening for Diabetic Retinopathy

NCT01614327
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
VisionQuest Biomedical LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
19,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

NCT01064505
View directory record Official record
Conditions
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 at various doses
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

NCT05542381
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
Drug · Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

NCT04567745
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
Interventions
Retinal fundus photography
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Telemedicine Retinal Screening Utilizing a Mobile Medical Unit

NCT01412905
View directory record Official record
Conditions
Diabetes, Retinopathy
Interventions
Not listed
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
16 Years to 80 Years
Enrollment
1,229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

NCT07218770
View directory record Official record
Conditions
Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions
REGN7041
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

NCT05135195
View directory record Official record
Conditions
Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

NCT01445899
View directory record Official record
Conditions
Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated No phase listed Observational

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

NCT01994174
View directory record Official record
Conditions
Macular Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Sep 9, 2026, 7:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Retinal Vessel Measurements as Clinically Useful Predictors in Veterans

NCT01772173
View directory record Official record
Conditions
Diabetes
Interventions
Vessel measurements
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated No phase listed Observational

Effect of Panretinal Photocoagulation on Optic Nerve Head Topography

NCT00767884
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Not applicable Interventional

30g vs 33g Needle for Intravitreal Injections

NCT03038048
View directory record Official record
Conditions
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Varying needle size with intravitreal ranibizumab or aflibercept
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 9, 2026, 7:24 AM EDT
Not listed No phase listed Observational

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

NCT05566717
View directory record Official record
Conditions
Diabetic Retinopathy, Neurotrophic Keratitis
Interventions
Not listed
Lead sponsor
Medical Center Ophthalmology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 9, 2026, 7:24 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Automated AI-based System for Early Diagnosis of Diabetic Retinopathy

NCT05324189
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Referable versus Non Referable Diabetic Retinopathy diagnostic test
Diagnostic Test
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of PER-001 in Participants With Diabetic Retinopathy

NCT06003751
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients

NCT02099981
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aminoguanidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 9, 2026, 7:24 AM EDT